For instance, combinations of statins, inhibitors of HMG-CoA-reductase (HMGCR), with distinct other cholesterol-lowering medications including NPC1L1, PCSK9 and APOB inhibitors have been demonstrated to lower LDLc levels and CAD risk further than statin treatment alone9,10. This evidence concerns the gene APOB and coronary artery disorder.